Sol-Gel Technologies (SLGL) Competitors $21.90 -0.05 (-0.23%) Closing price 03:54 PM EasternExtended Trading$22.30 +0.40 (+1.83%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLGL vs. CHEK, DRCT, SLS, ENTA, LFVN, ACTU, NKTX, NVCT, CYBN, and BIOAShould you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Check-Cap (CHEK), Direct Digital (DRCT), SELLAS Life Sciences Group (SLS), Enanta Pharmaceuticals (ENTA), Lifevantage (LFVN), Actuate Therapeutics (ACTU), Nkarta (NKTX), Nuvectis Pharma (NVCT), Cybin (CYBN), and BioAge Labs (BIOA). Sol-Gel Technologies vs. Its Competitors Check-Cap Direct Digital SELLAS Life Sciences Group Enanta Pharmaceuticals Lifevantage Actuate Therapeutics Nkarta Nuvectis Pharma Cybin BioAge Labs Sol-Gel Technologies (NASDAQ:SLGL) and Check-Cap (NASDAQ:CHEK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Is SLGL or CHEK more profitable? Check-Cap has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -14.25%. Check-Cap's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Sol-Gel Technologies-14.25% -11.80% -9.39% Check-Cap N/A N/A N/A Which has more volatility and risk, SLGL or CHEK? Sol-Gel Technologies has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Do institutionals & insiders believe in SLGL or CHEK? 26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 0.5% of Check-Cap shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher earnings & valuation, SLGL or CHEK? Sol-Gel Technologies has higher revenue and earnings than Check-Cap. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSol-Gel Technologies$11.54M5.29-$10.58M-$1.23-17.80Check-CapN/AN/A-$17.57M-$3.00-0.21 Does the media refer more to SLGL or CHEK? In the previous week, Sol-Gel Technologies had 2 more articles in the media than Check-Cap. MarketBeat recorded 3 mentions for Sol-Gel Technologies and 1 mentions for Check-Cap. Check-Cap's average media sentiment score of 1.88 beat Sol-Gel Technologies' score of 0.90 indicating that Check-Cap is being referred to more favorably in the news media. Company Overall Sentiment Sol-Gel Technologies Positive Check-Cap Very Positive SummarySol-Gel Technologies beats Check-Cap on 7 of the 12 factors compared between the two stocks. Get Sol-Gel Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLGL vs. The Competition Export to ExcelMetricSol-Gel TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.15M$4.18B$5.78B$9.80BDividend YieldN/A1.29%3.95%4.02%P/E Ratio-17.8011.1031.2626.59Price / Sales5.2914.88454.13168.41Price / CashN/A7.1037.7359.36Price / Book1.914.8010.046.68Net Income-$10.58M-$109.62M$3.27B$265.59M7 Day Performance-15.12%-3.02%3.17%3.42%1 Month Performance82.35%16.91%4.34%1.09%1 Year Performance223.96%31.13%44.12%23.84% Sol-Gel Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLGLSol-Gel Technologies0.7894 of 5 stars$21.90-0.2%N/A+229.7%$61.15M$11.54M-17.8050Gap UpCHEKCheck-Cap0.6809 of 5 stars$0.66-0.6%N/A-66.3%$3.89MN/A-0.2280DRCTDirect Digital2.4918 of 5 stars$0.40-3.2%$6.00+1,412.5%-86.5%$9.23M$62.29M-0.2260Gap DownSLSSELLAS Life Sciences Group2.8906 of 5 stars$1.73+6.1%$7.00+304.6%+42.2%$171.63M$1M-5.4110ENTAEnanta Pharmaceuticals3.7858 of 5 stars$8.17+2.1%$21.67+165.2%-34.4%$171.02M$64.81M-1.89160Gap UpLFVNLifevantage4.0459 of 5 stars$13.69+1.5%$30.50+122.8%+53.3%$169.81M$222.35M19.84260News CoveragePositive NewsDividend AnnouncementACTUActuate TherapeuticsN/A$8.25+1.6%$20.50+148.5%+0.0%$166.22MN/A0.0010Trending NewsAnalyst ForecastAnalyst RevisionGap DownNKTXNkarta2.1327 of 5 stars$2.35+0.9%$13.60+478.7%-58.4%$165.49MN/A-1.59140NVCTNuvectis Pharma3.518 of 5 stars$6.45+0.3%$15.33+137.7%-4.6%$163.69MN/A-5.518CYBNCybin2.3887 of 5 stars$6.92-2.0%$85.00+1,128.3%N/A$163.24MN/A-1.5850BIOABioAge LabsN/A$4.52-0.7%N/AN/A$163.12M$3.86M0.00N/A Related Companies and Tools Related Companies Check-Cap Alternatives Direct Digital Alternatives SELLAS Life Sciences Group Alternatives Enanta Pharmaceuticals Alternatives Lifevantage Alternatives Actuate Therapeutics Alternatives Nkarta Alternatives Nuvectis Pharma Alternatives Cybin Alternatives BioAge Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLGL) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sol-Gel Technologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sol-Gel Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access